Multiple Myeloma Hub

Multiple Myeloma Hub

Por: Scientific Education Support
The Multiple Myeloma Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in multiple myeloma. Our aim is to enhance knowledge in multiple myeloma, through the multichannel dissemination of global advances related to their classification, diagnosis, treatment, and management. Hosted on Acast. See acast.com/privacy for more information.
77 episodios disponibles

Latest episodes of the podcast Multiple Myeloma Hub

Mostrando página 2 de 4

What is the impact of belantamab mafodotin on QoL in patients with MM? 30/04/2025
What is the impact of elranatamab on quality of life in relapsed/refractory multiple myeloma? 29/04/2025
Symposium | The next wave of immune-based therapies: What you need to know in relapsed/refractory multiple myeloma 13/08/2024
Integrating cilta-cel into earlier lines of therapy: Rationale and latest data from CARTITUDE-2 and CARTITUDE-4 09/08/2024
Symposium | How to sequence CAR T-cell therapy and bispecific antibodies in relapsed/refractory multiple myeloma 09/08/2024
Teclistamab: real-world safety and efficacy 08/08/2024
Infections associated with bispecific antibodies 16/07/2024
CAR T-cell therapies in clinical practice 16/07/2024
How to select maintenance therapies post-ASCT for patients with high-risk MM? 18/09/2023
Should risk-adapted MM treatment be informed by age or frailty status? 12/09/2023
How is the immune reconstitution in patients who stop therapy after achieving MRD negativity? 09/02/2023
What are the main discrepancies between MM treating centers in Brazil? 06/02/2023
What are the initial data of dara-CyBorD in patients with extramedullary disease? 03/02/2023
Which patients might benefit the most from isatuximab-based combinations in the relapsed setting? 02/10/2022
Integrating BCMA-directed agents in the treatment landscape for relapsed/refractory MM 05/08/2022
The role of consolidation after autologous stem cell transplantation 05/08/2022
What are the pros and cons of bispecific antibodies for multiple myeloma? 25/07/2022
Combining bispecific antibodies with monoclonal antibodies to treat relapsed/refractory MM 21/04/2022
Daratumumab as maintenance therapy for transplant-eligible patients with NDMM: What have we learned from GRIFFIN and CASSIOPEIA trials? 14/01/2022
Managing infections with novel immunotherapies: Prevention, treatment, and impact on the QoL of patients with MM 09/11/2021
« Primera ‹ Anterior 1 2 3 4 Siguiente › Última »
© 2003-2026 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA